104 related articles for article (PubMed ID: 35863088)
1. SR 57227A, a serotonin type-3 receptor agonist, as a candidate analgesic agent targeting nociplastic pain.
Nakamura Y; Sumi T; Mitani O; Okamoto T; Kubo E; Masui K; Kondo M; Koyama Y; Usui N; Shimada S
Biochem Biophys Res Commun; 2022 Sep; 622():143-148. PubMed ID: 35863088
[TBL] [Abstract][Full Text] [Related]
2. SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo.
Bachy A; Héaulme M; Giudice A; Michaud JC; Lefevre IA; Souilhac J; Manara L; Emerit MB; Gozlan H; Hamon M
Eur J Pharmacol; 1993 Jun; 237(2-3):299-309. PubMed ID: 7689975
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of NMDA-receptor mediated response in the rat medial prefrontal cortical pyramidal cells by the 5-HT3 receptor agonist SR 57227A and 5-HT: intracellular studies.
Liang X; Arvanov VL; Wang RY
Synapse; 1998 Jul; 29(3):257-68. PubMed ID: 9635896
[TBL] [Abstract][Full Text] [Related]
4. Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents.
Poncelet M; Perio A; Simiand J; Gout G; Soubrie P; Le Fur G
J Neural Transm Gen Sect; 1995; 102(2):83-90. PubMed ID: 8748673
[TBL] [Abstract][Full Text] [Related]
5. SR 57227A is a partial agonist/partial antagonist of 5-HT
Nakamura Y; Kondo M; Koyama Y; Shimada S
Biochem Biophys Res Commun; 2019 Jan; 508(2):590-596. PubMed ID: 30509492
[TBL] [Abstract][Full Text] [Related]
6. Serotonin3 receptor agonists attenuate glutamate-induced firing in rat hippocampal CA1 pyramidal cells.
Zhang JY; Zeise ML; Wang RY
Neuropharmacology; 1994; 33(3-4):483-91. PubMed ID: 7984287
[TBL] [Abstract][Full Text] [Related]
7. High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and affective conditioning.
Colpaert FC; Deseure K; Stinus L; Adriaensen H
J Pharmacol Exp Ther; 2006 Feb; 316(2):892-9. PubMed ID: 16254131
[TBL] [Abstract][Full Text] [Related]
8. Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain.
Bardin L; Tarayre JP; Malfetes N; Koek W; Colpaert FC
Pharmacology; 2003 Apr; 67(4):182-94. PubMed ID: 12595749
[TBL] [Abstract][Full Text] [Related]
9. Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats.
Berrocoso E; De Benito MD; Mico JA
Psychopharmacology (Berl); 2007 Jul; 193(1):97-105. PubMed ID: 17393145
[TBL] [Abstract][Full Text] [Related]
10. The novel analgesic and high-efficacy 5-HT1A receptor agonist, F 13640 induces c-Fos protein expression in spinal cord dorsal horn neurons.
Buritova J; Tarayre JP; Besson JM; Colpaert F
Brain Res; 2003 Jun; 974(1-2):212-21. PubMed ID: 12742639
[TBL] [Abstract][Full Text] [Related]
11. The pyramidal neurons in the medial prefrontal cortex show decreased response to 5-hydroxytryptamine-3 receptor stimulation in a rodent model of Parkinson's disease.
Zhang QJ; Li LB; Niu XL; Liu J; Gui ZH; Feng JJ; Ali U; Hui YP; Wu ZH
Brain Res; 2011 Apr; 1384():69-79. PubMed ID: 21291871
[TBL] [Abstract][Full Text] [Related]
12. Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.
Altarifi AA; Rice KC; Negus SS
J Pharmacol Exp Ther; 2015 Feb; 352(2):208-17. PubMed ID: 25406170
[TBL] [Abstract][Full Text] [Related]
13. Opioid and adjuvant analgesics: compared and contrasted.
Khan MI; Walsh D; Brito-Dellan N
Am J Hosp Palliat Care; 2011 Aug; 28(5):378-83. PubMed ID: 21622486
[TBL] [Abstract][Full Text] [Related]
14. In vivo modulation of the firing activity of putative slow- and fast-spiking interneurons in the medial prefrontal cortex by 5-HT3 receptors in 6-hydroxydopamine-induced Parkinsonian rats.
Gui ZH; Zhang QJ; Liu J; Ali U; Li LB; Wang Y; Wang T; Chen L; Hou C; Fan LL
Neuroscience; 2010 Sep; 169(3):1315-25. PubMed ID: 20576497
[TBL] [Abstract][Full Text] [Related]
15. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.
Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW
Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045
[TBL] [Abstract][Full Text] [Related]
16. Antinociceptive effects of pluronic lecithin organo (PLO)-opioid gels in rats with thermal injury.
Clifford JL; Christy RJ; Cheppudira BP
Burns; 2017 Dec; 43(8):1709-1716. PubMed ID: 28778760
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of morphine analgesic effects in the sensory and affective components of formalin-induced spontaneous pain in male and female rats.
Harton LR; Richardson JR; Armendariz A; Nazarian A
Brain Res; 2017 Mar; 1658():36-41. PubMed ID: 28089665
[TBL] [Abstract][Full Text] [Related]
18. Analgesic activity of ZC88, a novel N-type voltage-dependent calcium channel blocker, and its modulation of morphine analgesia, tolerance and dependence.
Meng G; Wu N; Zhang C; Su RB; Lu XQ; Liu Y; Yun LH; Zheng JQ; Li J
Eur J Pharmacol; 2008 May; 586(1-3):130-8. PubMed ID: 18374913
[TBL] [Abstract][Full Text] [Related]
19. The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures.
Parenti C; Turnaturi R; Aricò G; Gramowski-Voss A; Schroeder OH; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
Neuropharmacology; 2013 Aug; 71():70-82. PubMed ID: 23541722
[TBL] [Abstract][Full Text] [Related]
20. Effects of the high-efficacy 5-HT1A receptor agonist, F 13640 in the formalin pain model: a c-Fos study.
Buritova J; Larrue S; Aliaga M; Besson JM; Colpaert F
Eur J Pharmacol; 2005 May; 514(2-3):121-30. PubMed ID: 15910798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
